<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01029132</url>
  </required_header>
  <id_info>
    <org_study_id>2007-04-021</org_study_id>
    <nct_id>NCT01029132</nct_id>
  </id_info>
  <brief_title>Characteristics of Treatment Responders to Galantamine</brief_title>
  <official_title>Characteristics of Treatment Responders to Galantamine Administration in the Patients With Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Korea, Ltd., Korea</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the characteristics of treatment responders to galantamine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purposes of this study are:

        1. to investigate the characteristics of treatment responders to galantamine by examining
           the clinical response of galantamine in patients with mild to moderate AD for 52 weeks.

        2. to examine the specific cognitive sub-domains that are more sensitive to galantamine
           administration.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alzheimer's Disease Assessment Scale-cognitive subscale-preliminary Korean version (ADAS-cog-K)</measure>
    <time_frame>baseline, 4w, 13w, 26w, 39w, 52w</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seoul-Activities of Daily Living (S-ADL) Seoul-Instrumental Activities of Daily Living (S-IADL) Korean version Neuropsychiatric Inventory (K-NPI)</measure>
    <time_frame>baseline, 4w, 13w, 26w, 39w, 52w</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>non-responder group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients who did not maintained or improved cognitive function</description>
  </arm_group>
  <arm_group>
    <arm_group_label>responder group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients who maintained or improved cognitive function</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>galantamine</intervention_name>
    <description>8 mg/day (4 mg bid) during the first 4 weeks, up to a maximum of 24 mg/day (12 mg bid) at intervals of 4 weeks, from 16 to 24 mg/day based on the patient's tolerability</description>
    <arm_group_label>non-responder group</arm_group_label>
    <arm_group_label>responder group</arm_group_label>
    <other_name>galantamine-reminyl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A diagnosis of probable AD according to the criteria of the NINCDS-ADRDA

          2. Korean version Mini-Mental State Examination scores between 10 and 26

          3. History of cognitive decline that had been gradual in onset and progressive over at
             least 6 months

          4. A caregiver who could assist the patient with medication, attend the assessment and
             provide information about the patient.

        Exclusion Criteria:

          1. they had evidence of any neurodegenerative diseases other than AD (i.e. Parkinson's
             disease, Huntington's disease)

          2. Psychiatric disorder or severe behavioral disturbances that required psychotropic
             medications

          3. Cerebral injuries induced by trauma, hypoxia, and/or ischemia

          4. Clinically active cerebrovascular disease; History of seizure disorder

          5. Other physical conditions that required acute treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doh Kwan Kim, PhD, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2009</study_first_submitted>
  <study_first_submitted_qc>December 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2009</study_first_posted>
  <last_update_submitted>January 4, 2016</last_update_submitted>
  <last_update_submitted_qc>January 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Doh Kwan Kim</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>Galantamine</keyword>
  <keyword>Treatment response</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Adverse Event</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Galantamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

